After being fired, I became the light of medicine

Chapter 110: Shock! The giant Novartis has developed a special drug for fatty liver disease! (Additional chapter for the dust blown away by the wind 0)

Zhang Yang ultimately rejected Friedman's strategy.

From the beginning to the end, his original intention in developing this "hepatocyte activator" was to save the fate of a generation and save the fate of those patients who developed cirrhosis due to hepatitis B.

For example, Liu Wenjun from the age of 12 to 52.

If the "liver activator" only has a 50% therapeutic effect, it will be like the results of the Phase I clinical trial. It may be able to maintain the condition but it will never be reversed, and countless patients with cirrhosis will still be on the verge of death.

After all, cirrhosis is not fatty liver.

but.

Friedman’s words still moved Zhang Yang.

There are more than 1.2 million patients with fatty liver in China. The current 50% activator samples can indeed relieve and protect the liver. There is no reason not to make money from this.

He began to wonder whether he should start a new project, or simply make 50% of the samples into health products, which would also make it easier for patients with fatty liver to purchase them themselves.

In this way, the complete product of "hepatocyte activator" can be classified as a medicine, and the one with 50% effect can be turned into a health product, thus distinguishing the two.

"Alas, it's still corrupted!"

Zhang Yang sighed and kept this matter in mind. Next, he would have to carefully learn about the declaration and approval of health products.

And the other side.

After Friedman obtained Zhang Yang's permission to re-sign the agreement, he immediately flew back to the United States to begin recruiting patients for the second phase of clinical trials.

This time, there were only 98 people in their Phase II clinical trial, and Novartis recruited enough patients in just one week.

Of course, almost all of the 98 patients were patients with severe fatty liver and cirrhosis caused by fatty liver, and the "liver cell regeneration activator" project was renamed "fatty liver activator";
At the same time, the treatment direction was adjusted from the previous "cirrhosis and fatty liver" to "fatty liver and cirrhosis".

Everything was going smoothly, and before we knew it, Novartis' progress in the FDA was significantly faster than that of Tsingshan Pharmaceutical.

About a month later, Tsingshan Pharmaceutical's "liver activator" finally passed the domestic Phase II clinical approval and was officially able to start Phase II clinical trials.

Tsingshan Pharmaceutical's Phase II clinical trial is designed to last for three months, with a total of 94 subjects with cirrhosis.

The difference between Novartis' Phase II clinical trial and Tsingshan Pharmaceutical's is that Novartis' patients are mainly patients with severe fatty liver disease, while 90% of patients in Tsingshan Pharmaceutical's trial are patients with liver cirrhosis caused by hepatitis B.
This makes a huge difference in the clinical trials on both sides, one is inclined towards fatty liver and the other is inclined towards cirrhosis.

While Tsingshan Pharmaceutical has just started recruiting subjects, Novartis has already started the Phase II clinical trial, and the first month's clinical data of the first batch of 20 subjects has been released.

Soon after, the clinical data of the second, third and fourth batches of more than 80 people were also counted.

After seeing the data, Novartis executives breathed a sigh of relief. After expanding the number of subjects in the Phase II clinical trial, the clinical treatment effect remained very stable. Slight changes began to appear in the experimental and control groups, and such changes will become more and more obvious with continued medication!
really.

When the data results for the second month were tabulated, there was already a clear gap between the performance of the two sets of data for the two months.

The transaminase level in the experimental group decreased slowly, liver inflammation indicators showed significant improvement, and liver elasticity began to return to normal values.

With a large amount of clinical data and the analysis of the drug ingredients of "hepatocyte activator" in Novartis laboratories, Novartis executives from the president to the head of the R&D center are almost certain that there is a 99% chance that this drug will pass the Phase III clinical trial and be marketed!

"President Green, we will successfully complete the Phase II clinical trial in half a month."

"There are no repeated modifications to the ingredients, no repeated changes to the dosage, and our drug is mainly for patients with fatty liver disease. I think we will be able to start Phase III clinical trials soon and even quickly go on the market!"

"I suggest that we start publicizing this to the public. Medical journals, biology professors, and the media can all start reporting on this!"

"There are 5000 million people with severe fatty liver disease in our country, and there are countless more with common fatty liver disease. Once the news is reported, it will definitely attract everyone's attention, which will also be a great help to our subsequent sales!"

Friedman's proposal was quickly approved by President Green.

Three days later, a piece of news about Novartis developing a drug that can treat "fatty liver" appeared in a medical journal. After being reprinted by many media outlets,
The new name of "hepatocyte activator" in the United States, "LivClearX", appeared in the public eye for the first time.

“LivClearX! Liv is the abbreviation of Liver, and Clear means to clear. It clears liver toxins. What a great name!”

"The drug ingredient in LivClearX is an active enzyme that has an excellent therapeutic effect on fatty liver. It can effectively relieve liver inflammation and restore the liver to health..."

"Long-term use can accelerate the decomposition of liver fat and reduce the risk of cirrhosis and liver cancer!"

"Oh my god, is this true? This is definitely the best news I've heard this year!"

"Really? Of course it's true. I've checked the FDA website and found that the 'LivClearX' drug filed by Novartis has completed its Phase II clinical trial and the clinical data is very good!"

"Really? Damn it! I just found out about this now. I already weigh 300 pounds. The doctor said my liver is full of fat. If I don't lose weight, I won't be able to save my liver! When will this drug be available on the market?"

Discussions about Novartis' new drug "LivClearX" on Twitter suddenly increased, and 20-year-old Anderson, who has been testing drugs for a long time, also saw the news. He quickly sent the most popular reports to the "drug testing group" and @ his friend James.

"James! Don't you suspect that the medicine I take is ineffective? Look, there is a report on this medicine in the New England Journal of Medicine! It can protect the liver and even break down fat. Do you see it?!"

"I see, Shit! The results of the Phase II clinical trial are actually effective. Can you tell me what it really feels like?"

"Very good! I have been taking it for two months in the Phase I clinical trial, and now I am in the trial group in the Phase II clinical trial. I have been taking it for four months! My transaminase will soon be normal, and I feel like my liver has been reborn!"

"They are about to start Phase III clinical trials, and I will continue to apply for the trial!"

"Oh, Anderson, if the product is launched after the Phase III clinical trial, will you buy it?"

"Yes! Of course! I will take it every day just like you eat chocolate. Now you can guess how much a box costs."

"Haha, Anderson, I guess you can't afford it!"

"Fuck!"

Anderson is indeed becoming more and more fond of this drug for treating fatty liver disease, and he has already made up his mind to continue participating in the Phase III clinical trial.

Even though there is no compensation for Phase III clinical trials, he will still participate.

Gradually, as Novartis began advertising and many test subjects posted some test results on the Internet, the fame and information of the new drug "LivClearX" spread little by little.

Zhang Xiaohua is a medical student and also has his own public account related to medicine.

With his excellent English skills, he often posts the research and development progress of some popular foreign drugs on his official account.

On this day, he accidentally discovered a new drug called "LivClearX".

“A new drug that can effectively relieve liver inflammation and has an excellent therapeutic effect on fatty liver disease?”

"At the same time, long-term use can prevent the further development of cirrhosis, purify the liver microenvironment, and reduce the risk of cirrhosis and liver cancer!"

"R&D company—Novartis!"

"Oh my god! Novartis has released a new drug without any announcement! We must move back to China. There are so many patients with fatty liver and cirrhosis in China. Now there is hope for these patients!"

Zhang Xiaohua organized and translated the information from the external network overnight, and in the early morning of the same day, he posted the news on his public account.

[Latest news! Pharmaceutical giant Novartis develops a special drug to treat fatty liver and cirrhosis! ]

Early the next morning,
This article immediately caught the attention of a medical media and was reprinted immediately. That afternoon, it attracted a small amount of attention in the medical circle.

Many medical professionals began to inquire about the authenticity of the news, and many people started discussing it.

Everyone remembers clearly that about half a year ago, Tsingshan Pharmaceutical announced that it had found an activating substance that can effectively regenerate liver cells.

It seems that their new drug has just started the second phase of clinical trials?

But Novartis has already publicized it and seems to be preparing for Phase III clinical trials and then going on the market!

Oh my goodness, Qingshan Pharmaceutical is going to be intercepted? !

As discussions grow, on the other hand, it has to be said that Novartis is indeed a world-renowned giant.

With the name of Novartis and keywords such as "cirrhosis" and "fatty liver", the article was quickly forwarded to WeChat friends circles, and patient groups.

Among them, the cirrhosis patient group of Chengdu Third People's Hospital also received forwarding messages from several patients.

In fact, most of the patients in the group have only joined in the last two or three months. They were transferred here after seeing that Qingshan Pharmaceutical started clinical trials of "hepatocyte activators" here, hoping to get a number and use the new drug.

However, the effect of the "hepatocyte regeneration activator" in the first clinical phase was not very obvious, and the evaluation of patients participating in the trial was also very general. Compared with Qingshan Pharmaceutical's previous "ITG myeloid factor" and "Abrofovir", its reputation was much worse.

This made many patients who had high hopes for Qingshan Pharmaceutical feel a little disappointed.

The Phase II clinical trial of the "hepatocyte activator" only recruited 94 people, and the vast majority of patients did not get a place.

The news of Novartis' new drug "LivClearX" immediately attracted the attention of many domestic patients with liver cirrhosis.

……

PS: I will update more chapters for the dust blown away by the wind. There are 0 chapters left for rewards.

(End of this chapter)